New imaging agent could sharpen detection of blood cancers
NCT ID NCT02128945
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new radioactive tracer called [18F]-Fludarabine for PET scans in 10 people with untreated chronic lymphocytic leukemia or diffuse large B-cell lymphoma. The goal was to see how the tracer spreads in the body and how well it highlights cancer cells. If it works, it could offer a more accurate way to image these cancers than the current standard tracer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [18F]-Fludarabine (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this could lead to a more accurate PET scan for detecting and monitoring certain blood cancers, especially chronic lymphocytic leukemia.
- What could go wrong
- This is a very early, small study (10 people) focused on safety and imaging, not treatment. The new tracer may not prove better than the current standard scan.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital
Caen, 14000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?